Sugi Predict

Sugi Predict / Compounds / SCHEMBL2321652

SCHEMBL2321652

SCHEMBL2321652

COc1cc(B2OC(C)(C)C(C)(C)O2)c(F)cc1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.37
▸ ALDH1A1 P00352 5/20 0.37
▸ CYP3A4 P08684 3/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ GAA P10253 2/20 0.36
▸ LPL P06858 1/20 0.33
▸ LIPG Q9Y5X9 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ S100B P04271 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ APP P05067 1/20 0.31
▸ CSF1R P07333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30316392 1.00 EGFR (0.37) EGFRALDH1A1CYP3A4TDP1TSHR
SCHEMBL19668082 0.83 LPL (0.38) ALDH1A1LPLLIPG
SCHEMBL22687004 0.82 GAA (0.43) EGFRALDH1A1CYP3A4TDP1TSHR
SCHEMBL14406854 0.82 EGFR (0.39) EGFRALDH1A1LPLLIPGHTT
SCHEMBL59040 0.82 LPL (0.37) ALDH1A1LPLLIPG
SCHEMBL29385065 0.82 LPL (0.37) ALDH1A1LPLLIPG
SCHEMBL31118339 0.81 EGFR (0.44) EGFRALDH1A1TSHRPOLBGAA
SCHEMBL24745863 0.79 EGFR (0.38) EGFRPOLBGAALPLLIPG
SCHEMBL31255125 0.79 ALDH1A1 (0.46) EGFRALDH1A1CYP3A4TDP1TSHR
SCHEMBL21067074 0.79 CYP3A4 (0.35) ALDH1A1CYP3A4TDP1TSHRLPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
US-20250034187-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2025-01-30 — — US disclosed
US-12152049-B2 STING agonistic compound ONO PHARMACEUTICAL CO., LTD. (JP) 2024-11-26 — — US disclosed
US-11919917-B2 Sting agonistic compound ONO PHARMACEUTICAL CO., LTD. (JP) 2024-03-05 — — US disclosed
CN-112867721-B STING agonistic compounds 小野药品工业株式会社 2023-12-08 — — CN disclosed
US-20230339992-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 — — US disclosed
US-20230151024-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-18 — — US disclosed
US-20230141284-A1 CANCER THERAPEUTIC METHOD ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-11 — — US disclosed
EP-4134098-A1 METHOD OF CANCER THERAPY ONO Pharmaceutical Co., Ltd. (JP) 2023-02-15 — — EP disclosed
EP-4134134-A1 STING AGONISTIC COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2023-02-15 — — EP disclosed
US-20210363166-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2021-11-25 — — US disclosed
US-11130773-B2 STING agonistic compound ONO PHARMACEUTICAL CO., LTD. (JP) 2021-09-28 — — US disclosed
US-20210253615-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2021-08-19 — — US disclosed
EP-2534151-B1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MERCK SHARP & DOHME (NL) 2018-11-14 — — EP disclosed
US-8658794-B2 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof MERCK SHARP & DOHME B.V. (NL) 2014-02-25 — — US disclosed
EP-2534151-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MSD Oss B.V. (NL) 2012-12-19 — — EP disclosed
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2012-12-06 — — US disclosed
WO-2011095556-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2011-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141284-A1 CANCER THERAPEUTIC METHOD STING1, CGAS, IFNAR1 EGFR 649/4885ALDH1A1 3843/4885CYP3A4 1883/4885
US-20250034187-A1 STING AGONISTIC COMPOUND STING1, IRF3, MAVS EGFR 876/4885ALDH1A1 4495/4885CYP3A4 4539/4885
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 EGFR 455/4885ALDH1A1 2085/4885CYP3A4 567/4885
US-20210363166-A1 STING AGONISTIC COMPOUND STING1, IRF3, MAVS EGFR 876/4885ALDH1A1 4495/4885CYP3A4 4539/4885
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS LCK, ZAP70, FYN EGFR 1575/4885ALDH1A1 2434/4885CYP3A4 2344/4885
US-11130773-B2 STING agonistic compound STING1, IRF3, MAVS EGFR 876/4885ALDH1A1 4495/4885CYP3A4 4539/4885
US-20230151024-A1 STING AGONISTIC COMPOUND STING1, CGAS, TLR1 EGFR 990/4885ALDH1A1 3607/4885CYP3A4 3914/4885
US-12152049-B2 STING agonistic compound STING1, IRF3, MAVS EGFR 876/4885ALDH1A1 4495/4885CYP3A4 4539/4885
US-11919917-B2 Sting agonistic compound STING1, IRF3, MAVS EGFR 876/4885ALDH1A1 4495/4885CYP3A4 4539/4885
US-20210253615-A1 STING AGONISTIC COMPOUND STING1, IRF3, MAVS EGFR 876/4885ALDH1A1 4495/4885CYP3A4 4539/4885
US-20230339992-A1 STING AGONISTIC COMPOUND STING1, IRF3, MAVS EGFR 876/4885ALDH1A1 4495/4885CYP3A4 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.